Number of patients | (105) |
Demography |
|
-Age | 15 - 69 years (39.01 ± 9.72 years; median 38 years) |
-Sex ratio (M/F) | 2.74 |
Discovery circumstances | Screening (38.10%), fortuitous (56.19%), symptomatic (5.71%) |
Biological variables |
|
-HBV genotype | E (98) NP (7) |
-HBsAg quantification (N ˂ 0.05 IU/ml) | 1.69 - 6199 UI/ml (mean 12111.2 ± 10617.4; median 98.41) |
-HBV HBeAg-négatif | Active (96), inactive (9) |
-HBV DNA levels (N ˂ 20 IU/ml) | 154 - 1.7 (mean 4.4 e7 ± 7.5 e7; median 9685.5) |
-Transaminases ALAT (N ˂ 35 IU/ml) | 9 - 422 UI/ml (mean 38.62 ± 51.12; median 26) |
ASAT (N ˂ 40 IU/ml) | 10 - 313 UI/ml (mean 38.67 ± 41.88; median 27) |
-Prothrombine rate (N ≥ 70%) | 56% - 100% (mean 83.25 ± 8.13; median 83) |
-Triglycerid levels (N ˂ 2 gr/l) | 0.12 - 2.17 mg/l (mean 0.74 ± 0.35; median 0.70) |
-Creatinine (N ˂ 15 mg/l)) | 6 - 16.3 mg/l (mean 9.47 ± 1.72; median 9.1) |
-Platelets (N = 150 - 450 GIGA/L) | 24 - 389 GIGA/L (mean 186 ± 54; median 195) |
-Alpha Feto-protein (N ˂ 8.5 IU/ml) | 0.5 - 50.14 (mean 2.84 ± 5.35; median 1.51) |
Complex serum markers parameters |
|
-Total bilirubin (N ˂ 12.3 mg/L) | 2 - 54 mg/L (mean 11.63 ± 7.71; median 9.8) |
-Gammaglutamyl transferase (N ˂ 40 IU/ml) | 11 - 183 UI/L (mean 45.48 ± 34.38; median 34) |
-Haptoglobin levels (N = 0.58 - 1.55 g/L) | 0.1 - 1.87 g/L (mean 0.81 ± 0.5; median 0.83) |
-Apolipoprotein (N = 1.08 - 2.25 g/L) | 0.32 - 2.07 g/L (mean 1.30 ± 0.28; median 1.31) |
-Macroglobulin α2 (N = 1.75 - 4.20 g/L) | 1.02 - 5.25 g/L (mean 2.14 ± 0.71; median 1.97) |
-Fibrosis stage (F0-F4) | F0 (37), F1 (22), F2 (28), F3 (9), F4 (9). |
-Fibrosis score (0.00 - 1.00) | 0.03 - 0.96 (mean 0.34 ± 0.22; median 0.29) |
-Activity score (0.00 - 1.00) | 0.01 - 0.98 (mean 0.19 ± 0.20; median 0.13) |